Eli Lilly and Company (NYSE:LLY) Trading Down 1.2% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price fell 1.2% during mid-day trading on Tuesday . The stock traded as low as $1,229.79 and last traded at $1,231.9650. Approximately 2,124,000 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 3,090,796 shares. The stock had previously closed at $1,246.93.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA cleared an Alzheimer’s blood test developed by Lilly and Roche, potentially making disease testing more accessible and strengthening Lilly’s position in the Alzheimer’s market. FDA Nods Lilly-Roche’s Alzheimer’s Blood Test
• Positive Sentiment: Real-world data showed sustained Zepbound use among adults over 55 was associated with fewer hospital and emergency-room visits and lower healthcare costs, supporting Lilly’s argument that obesity drugs can deliver value to payers and potentially expand reimbursement. Zepbound Linked to Lower Healthcare Costs
• Positive Sentiment: Lilly’s oncology business is growing, while its Phase 3 RENEW-MDD-2 trial for brenipatide adds another potential long-term growth opportunity beyond Mounjaro and Zepbound. Lilly’s Brenipatide Enters Phase 3
• Neutral Sentiment: Lilly expanded its early-stage Alzheimer’s research pipeline with a new Phase 1 trial. The move supports long-term diversification, but clinical and commercial outcomes remain distant and uncertain. Lilly Expands Alzheimer’s Pipeline
• Negative Sentiment: Investor sentiment is being weighed down by reports that some employers are dropping or narrowing weight-loss-drug coverage, raising concerns about future Zepbound and oral GLP-1 volumes. Companies Decline to Cover Weight-Loss Drug Costs
• Negative Sentiment: Although Lilly’s cost-savings study supports Zepbound’s payer case, critics noted that it did not include the medicine’s price, leaving uncertainty about the treatment’s total economic value and reimbursement prospects. Lilly’s Cost-Saving Study Leaves Out Zepbound’s Price

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research note on Friday, August 7th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Guggenheim upped their target price on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company Stock Down 0.1%

The firm has a fifty day moving average price of $1,186.29 and a 200-day moving average price of $1,063.74. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market cap of $1.12 trillion, a price-to-earnings ratio of 39.86, a PEG ratio of 1.46 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 23.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last three months. 0.14% of the stock is owned by insiders.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in LLY. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $30,000. Maseco LLP grew its holdings in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its stake in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. increased its stake in Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.